High coverage of diverse invasive meningococcal serogroup B strains by the 4-component vaccine 4CMenB in Australia, 2007–2011: Concordant predictions between MATS and genetic MATS

References

• Acevedo R, Bai X, Borrow R, Caugant DA, Carlos J, Ceyhan M, Christensen H, Climent Y, De Wals P, Dinleyici EC, et al. The global meningococcal initiative meeting on prevention of meningococcal disease worldwide: epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations. Expert Rev Vaccines. 2019;18(1):15–30. doi:10.1080/14760584.2019.1557520.
   PubMed Web of Science ®Google Scholar
• Archer BN, Chiu CK, Jayasinghe SH, Richmond PC, McVernon J, Lahra MM, Andrews RM, McIntyre PB. Epidemiology of invasive meningococcal B disease in Australia, 1999-2015: priority populations for vaccination. Med J Aust. 2017;207(9):382–87. doi:10.5694/mja16.01340.
   PubMed Web of Science ®Google Scholar
• Australian Government- Department of Health. Invasive meningococcal disease national surveillance report - 1 January to 30 June 2019. [accessed 2020 Apr 20]. http://www1.health.gov.au/internet/main/publishing.nsf/Content/5FEABC4B495BDEC1CA25807D001327FA/$File/IMD-surveil-report-Jan-June-2019.pdf .
   Google Scholar
• Australian Government- Department of Health. Invasive meningococcal disease national surveillance report – 1 October to 31 December 2018. [accessed 2020 Apr 20]. http://www1.health.gov.au/internet/main/publishing.nsf/Content/5FEABC4B495BDEC1CA25807D001327FA/$File/1Oct-31Dec19-qrt3-IMD.pdf .
   Google Scholar
• Lawrence GL, Wang H, Lahra M, Booy R, McIntyre PB. Meningococcal disease epidemiology in Australia 10 years after implementation of a national conjugate meningococcal C immunization programme. Epidemiol Infect. 2016;144(11):2382–91. doi:10.1017/s0950268816000704.
   PubMed Web of Science ®Google Scholar
• Australian Government- Department of Health. National immunisation program schedule - from 1 April 2019. [accessed 2020 Apr 20]. http://www.health.gov.au/sites/default/files/national-immunisation-program-schedule-portrait.pdf .
   Google Scholar
• Giuliani MM, Adu-Bobie J, Comanducci M, Aricò B, Savino S, Santini L, Brunelli B, Bambini S, Biolchi A, Capecchi B, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A. 2006;103(29):10834–39. doi:10.1073/pnas.0603940103.
   PubMed Web of Science ®Google Scholar
• Budroni S, Siena E, Dunning Hotopp JC, Seib KL, Serruto D, Nofroni C, Comanducci M, Riley DR, Daugherty SC, Angiuoli SV, et al. Neisseria meningitidis is structured in clades associated with restriction modification systems that modulate homologous recombination. Proc Natl Acad Sci USA. 2011;108(11):4494–99. doi:10.1073/pnas.1019751108.
   PubMed Web of Science ®Google Scholar
• Siena E, Bodini M, Medini D. Interplay between virulence and variability factors as a potential driver of invasive meningococcal disease. Comput Struct Biotechnol J. 2018;16:61–69. doi:10.1016/j.csbj.2018.02.002.
   PubMed Web of Science ®Google Scholar
• Siena E, D’Aurizio R, Riley D, Tettelin H, Guidotti S, Torricelli G, Moxon ER, Medini D. In-silico prediction and deep-DNA sequencing validation indicate phase variation in 115 Neisseria meningitidis genes. BMC Genomics. 2016;17(1):843. doi:10.1186/s12864-016-3185-1.
   PubMedGoogle Scholar
• Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, Moxon ER, Stella M, Comanducci M, Bambini S, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA. 2010;107(45):19490–95. doi:10.1073/pnas.1013758107.
   PubMed Web of Science ®Google Scholar
• Medini D, Stella M, Wassil J. MATS: global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine. Vaccine. 2015;33(23):2629–36. doi:10.1016/j.vaccine.2015.04.015.
   PubMed Web of Science ®Google Scholar
• Budroni S, Kleinschmidt A, Boucher P, Medini D. Pooled-sera hSBA titres predict individual seroprotection in infants and toddlers vaccinated with 4CMenB. Vaccine. 2016;34(23):2579–84. doi:10.1016/j.vaccine.2016.04.009.
   PubMed Web of Science ®Google Scholar
• Frosi G, Biolchi A, Lo Sapio M, Rigat F, Gilchrist S, Lucidarme J, Findlow J, Borrow R, Pizza M, Giuliani MM, et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine. 2013;31(43):4968–74. doi:10.1016/j.vaccine.2013.08.006.
   PubMed Web of Science ®Google Scholar
• Muzzi A, Brozzi A, Serino L, Bodini M, Abad R, Caugant D, Comanducci M, Lemos AP, Gorla MC, Krizova P, et al. Genetic meningococcal antigen typing system (gMATS): a genotyping tool that predicts 4CMenB strain coverage worldwide. Vaccine. 2019;37(7):991–1000. doi:10.1016/j.vaccine.2018.12.061.
   PubMed Web of Science ®Google Scholar
• Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE, Urwin R, Zhang Q, Zhou J, Zurth K, Caugant DA, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA. 1998;95(6):3140–45. doi:10.1073/pnas.95.6.3140.
   PubMed Web of Science ®Google Scholar
• Lucidarme J, Comanducci M, Findlow J, Gray SJ, Kaczmarski EB, Guiver M, Vallely PJ, Oster P, Pizza M, Bambini S, et al. Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin Vaccine Immunol. 2010;17(6):919–29. doi:10.1128/cvi.00027-10.
   PubMed Web of Science ®Google Scholar
• Boccadifuoco G, Brunelli B, Mori E, Agnusdei M, Gianfaldoni C, Giuliani MM. Meningococcal antigen typing system (MATS): a tool to estimate global coverage for 4CMenB, a multicomponent meningococcal B vaccine. Methods Mol Biol. 2019;1969:205–15. doi:10.1007/978-1-4939-9202-7_14.
   PubMedGoogle Scholar
• Plikaytis BD, Stella M, Boccadifuoco G, DeTora LM, Agnusdei M, Santini L, Brunelli B, Orlandi L, Simmini I, Giuliani M, et al. Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Clin Vaccine Immunol. 2012;19(10):1609–17. doi:10.1128/cvi.00202-12.
   PubMed Web of Science ®Google Scholar
• Clark SA, Doyle R, Lucidarme J, Borrow R, Breuer J. Targeted DNA enrichment and whole genome sequencing of Neisseria meningitidis directly from clinical specimens. Int J Med Microbiol. 2018;308(2):256–62. doi:10.1016/j.ijmm.2017.11.004.
   PubMed Web of Science ®Google Scholar
• Rajam G, Stella M, Kim E, Paulos S, Boccadifuoco G, Serino L, Carlone G, Medini D. Meningococcal antigen typing system (MATS)-based Neisseria meningitidis serogroup B coverage prediction for the MenB-4C vaccine in the United States. mSphere. 2017;2:6. doi:10.1128/mSphere.00261-17.
   Web of Science ®Google Scholar
• Araya P, Diaz J, Seoane M, Fernandez J, Terrazas S, Canals A, Vaquero A, Barra G, Hormazabal JC, Pidal P, et al. [Laboratory surveillance for invasive meningococcal disease in Chile, 2006-2012]. Rev Chilena Infectol. 2014;31(4):377–84. doi:10.4067/s0716-10182014000400001.
   PubMed Web of Science ®Google Scholar
• Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, Stefanelli P, Caugant DA, Kriz P, Abad R, Bambini S, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013;13(5):416–25. doi:10.1016/s1473-3099(13)70006-9.
   PubMed Web of Science ®Google Scholar
• Mulhall RM, Bennett D, Cunney R, Borrow R, Lucidarme J, Findlow J, Jolley KA, Bray J, Maiden MCJ, Moschioni M, et al. Potential coverage of the 4CMenB vaccine against invasive serogroup B Neisseria meningitidis isolated from 2009 to 2013 in the Republic of Ireland. mSphere. 2018;3:4. doi:10.1128/mSphere.00196-18.
   Web of Science ®Google Scholar
• Lahra MM, Enriquez RP, Hogan TP. Australian meningococcal surveillance programme annual report, 2018. Commun Dis Intell. 2020:44. doi:10.33321/cdi.2020.44.10.
   Google Scholar
• Public Databases for Molecular Typing and Microbial Genome Diversity. Neisseria spp. [accessed 2020 29 Oct]. https://pubmlst.org/organisms/neisseria-spp .
   Google Scholar
• Abad R, Medina V, Stella M, Boccadifuoco G, Comanducci M, Bambini S, Muzzi A, Vazquez JA. Predicted strain coverage of a new meningococcal multicomponent vaccine (4CMenB) in Spain: analysis of the differences with other European countries. PLoS One. 2016;11(3):e0150721. doi:10.1371/journal.pone.0150721.
   PubMed Web of Science ®Google Scholar
• Parikh SR, Newbold L, Slater S, Stella M, Moschioni M, Lucidarme J, De Paola R, Giuliani M, Serino L, Gray SJ, et al. Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007-08 and 2014-15: a qualitative and quantitative assessment. Lancet Infect Dis. 2017;17(7):754–62. doi:10.1016/s1473-3099(17)30170-6.
   PubMed Web of Science ®Google Scholar
• Simoes MJ, Bettencourt C, De Paola R, Giuliani M, Pizza M, Moschioni M, Machado J. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Portugal. PLoS One. 2017;12(5):e0176177. doi:10.1371/journal.pone.0176177.
   PubMed Web of Science ®Google Scholar
• Tzanakaki G, Hong E, Kesanopoulos K, Xirogianni A, Bambini S, Orlandi L, Comanducci M, Muzzi A, Taha MK. Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine. BMC Microbiol. 2014;14:111. doi:10.1186/1471-2180-14-111.
   PubMed Web of Science ®Google Scholar
• Wasko I, Hong E, De Paola R, Stella M, Moschioni M, Taha MK, Skoczynska A. High predicted strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in Poland. Vaccine. 2016;34(4):510–15. doi:10.1016/j.vaccine.2015.11.070.
   PubMed Web of Science ®Google Scholar
• Bettinger JA, Scheifele DW, Halperin SA, Vaudry W, Findlow J, Borrow R, Medini D, Tsang R. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). Vaccine. 2013;32(1):124–30. doi:10.1016/j.vaccine.2013.03.063.
   PubMed Web of Science ®Google Scholar
• Mowlaboccus S, Mullally CA, Richmond PC, Howden BP, Stevens K, Speers DJ, Keil AD, Bjornstad ON, Perkins TT, Kahler CM. Differences in the population structure of Neisseria meningitidis in two Australian states: victoria and Western Australia. PLoS One. 2017;12(10):e0186839. doi:10.1371/journal.pone.0186839.
   PubMed Web of Science ®Google Scholar
• Stella M, Giuliani M, Biolchi A, Tomei S, De Paola R, Bai X, Borrow R, Lucidarme J, La Gaetana R, Toneatto D, et al. Does vaccination with 4CMenB convey protection against meningococcal serogroup B strains not predicted to be covered by MATS? A study of the UK clonal complex cc269. Hum Vaccin Immunother. 2020;16(4):945–48. doi:10.1080/21645515.2019.1688039.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Andrews N, Parikh SR, Campbell H, White J, Edelstein M, Bai X, Lucidarme J, Borrow R, Ramsay ME. Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. N Engl J Med. 2020;382(4):309–17. doi:10.1056/NEJMoa1901229.
   PubMed Web of Science ®Google Scholar
• Azzari C, Moriondo M, Nieddu F, Guarnieri V, Lodi L, Canessa C, Indolfi G, Giovannini M, Napoletano G, Russo F, et al. Effectiveness and impact of the 4CMenB vaccine against group B meningococcal disease in two italian regions using different vaccination schedules: a five-year retrospective observational study (2014-2018). Vaccines (Basel). 2020;8:3. doi:10.3390/vaccines8030469.
   Web of Science ®Google Scholar
• Government of South Australia - SA Health. Immunisation programs. 2020 [accessed 2020 Apr 20]. http://www.sahealth.sa.gov.au/wps/wcm/connect/public+content/sa+health+internet/conditions/immunisation/immunisation+programs/immunisation+programs .
   Google Scholar
• Rodrigues CMC, Jolley KA, Smith A, Cameron JC, Feavers IM, Maiden MCJ. Meningococcal deduced vaccine antigen reactivity (MenDeVAR) index: a rapid and accessible tool that exploits genomic data in public health and clinical microbiology applications. J Clin Microbiol. 2020. doi:10.1128/jcm.02161-20.
   PubMed Web of Science ®Google Scholar